# Alector, Inc. (ALEC) · Edgar & Edgarette company card

> Alector (ALEC) saw revenue fall 79.1% in FY2025 to $21 million, operating margin -741% against a -15.8% median for biological products, (no diagnostic substances), equity 10.5% of assets. Every figure is from the company’s own annual report filed with the SEC.

SEC CIK 1653087 · fiscal year ended 2025-12-31 · 5 audited years read · [page](https://www.pops4.com/boards/company/ALEC) · [JSON](https://www.pops4.com/boards/company/ALEC.json)

## Figures, as filed in the 10-K

| Measure | Value |
|---|---|
| Revenue | $21M |
| Revenue growth, 1 year | -79.1% |
| Revenue growth per year | -43.5% |
| Operating margin | -741.3% (prior year -144.2%) |
| Net margin | -679.2% |
| Operating cash flow | −$184M |
| Capital spending | $41,000 |
| Free cash flow | −$184M |
| Cash | $66M |
| Long-term debt | $10M |
| Total assets | $293M |
| Total equity | $31M |
| Equity ÷ assets | 10.5% |
| Return on equity | -466.3% |
| Dividend per share | — |
| Dividend years rising | — |

## Readings, computed from those figures

- Altman Z: -9.85 (distress zone)
- Piotroski F: 1 of 9 (weak)
- Health Harbor boat: Old boat · three warning signs · operating cash flow was negative; operating loss: a margin of -741.3% in FY2025; revenue is hard to predict: its 80% range is ±48%
- Cash Compass: In between · no clear cash pattern yet

## Edgarette's reading

Exposure: revenue $21.0M (FY2025), total debt $10.0M. Experience: revenue down 79.1% on the year, down 43.5% a year over 4 years; operating margin -741.3%, down from -144.2%. Soundness: equity 10.5% of assets, return on equity -466.3%. Credibility: four or more audited years, reasonable weight. Range: 80% of past cases like this landed between $4.6M and $13.1M next year (method v4.1: its own 4-year record of growth weighed at 50% against under $50M filers; across 2019–2025, 69.0% landed inside, 83.4% on the one year the method never saw). In a shock year the stress range is $4.3M to $14.1M. A statistical range, not company guidance. Against peers (31 filers, $50M+ revenue, biological products, (no diagnostic substances)): operating margin -741.3% against a -15.8% median; growth -79.1% against 21.4%.

Range logged 2026-10-06, receipt 0d2309102f6961bd, status open. A statistical range, not company guidance.

## Health Watch, last 12 months

- Item 5.02 Director or officer change: 2, latest 2026-10-14 ([filing](https://www.sec.gov/Archives/edgar/data/1653087/000119312526421080/0001193125-26-421080-index.htm))

## Recent filings

- 10-Q · filed 2026-11-05 · [filing](https://www.sec.gov/Archives/edgar/data/1653087/000119312526449871/0001193125-26-449871-index.htm)
- 8-K · filed 2026-11-05 · 2.02 Results of Operations and Financial Condition; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/1653087/000119312526449813/0001193125-26-449813-index.htm)
- 8-K · filed 2026-10-16 · 1.01 Entry into a Material Definitive Agreement; 8.01 Other Events; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/1653087/000119312526424204/0001193125-26-424204-index.htm)
- 8-K · filed 2026-10-14 · 5.02 Departure or Election of Directors; Appointment of Officers · [filing](https://www.sec.gov/Archives/edgar/data/1653087/000119312526421080/0001193125-26-421080-index.htm)
- 8-K · filed 2026-10-05 · 1.01 Entry into a Material Definitive Agreement; 2.02 Results of Operations and Financial Condition; 7.01 Regulation FD Disclosure; 8.01 Other Events; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/1653087/000119312526413090/0001193125-26-413090-index.htm)
- 10-Q · filed 2026-08-06 · [filing](https://www.sec.gov/Archives/edgar/data/1653087/000119312526338052/0001193125-26-338052-index.htm)

## Sources

- facts: https://data.sec.gov/api/xbrl/companyfacts/CIK0001653087.json
- filings: https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=1653087

## Cite

POPS4, Edgar & Edgarette: Alector, Inc. (ALEC) company card, from the company's own SEC filings, accessed 2026-11-21, https://www.pops4.com/boards/company/ALEC. CC BY 4.0. For a figure, add the filing URL under filings or sources.

DOI https://doi.org/10.5281/zenodo.23672509 · catalog https://www.pops4.com/boards/catalog.json · Figures as filed with the SEC. Card text CC BY 4.0, POPS4.

Reporting, not investment advice. No price targets and no trading recommendations.

Figures are as filed in audited 10-K reports and can move with restatements, acquisitions, disposals or a change in fiscal year. A range set from how past company-years turned out is not a promise about the next one, and says nothing about the share price.

